GlassScriptPhysician profile
Edwin L Kelsey
NPI 1932106895
$2,387.33
in general payments reported to CMS, 2019-2025
28 companies · $36.34 in 2025
The $36.34 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $102 · 2021: $377 · 2022: $879 · 2023: $537 · 2024: $220 · 2025: $36.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $371.85 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $269.33 | 2021-2024 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.96 | 2021-2025 | Relistor |
| Pfizer INC. | $163.87 | 2020-2023 | |
| Ibsa Pharma INC. | $153.31 | 2021-2024 | Tirosint, Licart, Licart |
| Scilex Pharmaceuticals INC. | $131.22 | 2020-2023 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $127.81 | 2022 | |
| Lilly USA, LLC | $120.94 | 2021-2023 | Emgality, Reyvow |
| Eisai INC. | $90.58 | 2021-2022 | |
| Daiichi Sankyo INC. | $83.42 | 2019 | |
| Redhill Biopharma INC. | $74.49 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.99 | 2019 | |
| Biodelivery Sciences International, INC. | $69.44 | 2019-2021 | |
| Grt US Holding, INC. | $62.32 | 2021-2022 | |
| Amgen INC. | $52.21 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.14 | 2021-2023 | Belsomra |
| Biohaven Pharmaceuticals, INC. | $38.41 | 2021 | |
| Horizon Therapeutics Plc | $29.44 | 2021-2022 | |
| Orexo US, INC. | $27.23 | 2021-2022 | |
| Almatica Pharma LLC | $24.95 | 2024 | Teriparatide |
| Upsher-Smith Laboratories LLC | $21.78 | 2022 | |
| Shionogi INC | $21.08 | 2019 | |
| Radius Health, INC. | $20.00 | 2019 | |
| Lundbeck LLC | $19.43 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.90 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $16.60 | 2022 | |
| Averitas Pharma INC. | $15.75 | 2023 | Qutenza |
| Arbor Pharmaceuticals, INC. | $14.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Kelsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.